## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Confirmation No.: 5359

DUBEY et al. Atty. Ref.: 4062-167

Appln. No. 10/540,556 T.C./Art Unit: 1621

Filed: December 13, 2005 Examiner: B.J. Davis

FOR: PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE (R) OR

(S)-5-(2-AMINOPROPYL)-2-METHOXYBENZENESULFONAMIDE

## TERMINAL DISCLAIMER

April 24, 2008

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Your petitioner, Cadila Healthcare Limited, a corporation having an office and place of business at Zydus Tower, Satellite Cross Roads, Ahmedabad, Gujarat, India 380 015 represents that it is the assignee as recorded starting at Reel 017875/Frame 0853 of all right, title and interest in and to Application No. 10/540,556, filed December 13, 2005, and entitled PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE (R) OR (S)-5-(2-AMINOPROPYL)-2-METHOXYBENZENESULFONAMIDE.

Your petitioner hereby disclaims the terminal part of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term as presently shortened by any terminal disclaimer of any patent issuing from Application No. 10/589,999 and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to such patent granted on the above-identified application shall be the same

as the legal title to any patent issuing from Application No. 10/589,999, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors or assigns.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term as presently shortened by any terminal disclaimer of any patent issuing from Application No. 10/589,999 in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

The evidentiary documents accompanying this document or referred to above have been reviewed by the undersigned and it is certified that to the best of the assignee's knowledge and belief, title is in the assignee seeking to take action.

Check either box 1 or 2 below, as appropriate.

- For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.
  - 2. 

    The undersigned is an attorney or agent of record.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements

DUBEY et al. - Appln. No. 10/540,556

and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may ieopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

## NIXON & VANDERHYE P.C.

By: /Gary R. Tanigawa/
Gary R. Tanigawa
Reg. No. 43,180

901 North Glebe Road, 11th Floor Arlington, VA 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

☑ Terminal disclaimer fee under 37 CFR § 1.20(d) included. If missing, the Director is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140.